Abritiga 250 mg Tablet 30's belongs to the group of medicines called androgen biosynthesis inhibitors that is indicated in combination with prednisone or prednisolone to treat prostate cancer in adult men that have spread to other body parts.

Abritiga 250 mg Tablet 30's contains ‘Abiraterone’ that works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer.

In some cases, Abritiga 250 mg Tablet 30's may cause common side effects such as diarrhoea, urinary tract infection, high blood pressure, low blood potassium, and oedema. If any of the side effects persist or worsen, consult your doctor.

Abritiga 250 mg Tablet 30's is not for use in women, children, and adolescents. Abritiga 250 mg Tablet 30's should not be given in combination with Ra-233 (a radioactive isotope used to treat prostate cancer) due to the increased risk of bone fracture or death. Inform your doctor about your health condition and medications to rule out any side effects/interactions.

Abritiga 250 mg Tablet 30's is used in the treatment of prostate cancer. The detailed uses of Abritiga 250 mg Tablet 30's are as follows:

• Treats advanced prostate cancer: Abritiga 250 mg Tablet 30's lowers levels of certain hormones (androgens) that fuel the growth of prostate cancer cells.
• Slows cancer progression: Abritiga 250 mg Tablet 30's helps delay the spread and worsening of prostate cancer.
• Improves overall management of prostate cancer: Abritiga 250 mg Tablet 30's is often used along with other medicines to enhance treatment effectiveness.

• Abritiga 250 mg Tablet 30's can be taken on an empty stomach, i.e., 1 hour before or 2 hours after food.
• Follow your doctor’s instructions on the dosage and timing of this medication to ensure safety.
• Swallow Abritiga 250 mg Tablet 30's as a whole with a glass of water.
• Do not chew, crush, or break it.

Abritiga 250 mg Tablet 30's belongs to the group of medicines called androgen biosynthesis inhibitors, indicated in combination with prednisone or prednisolone to treat prostate cancer in adult men that have spread to other body parts. Abritiga 250 mg Tablet 30's contains ‘Abiraterone’ that works by stopping the body from making testosterone, thereby slowing the growth of prostate cancer. It is indicated in patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel and metastatic high-risk castration-sensitive prostate cancer (CSPC). Abritiga 250 mg Tablet 30's is prescribed in the early stages of the disease, where it is still responding to hormone therapy. It is used with androgen deprivation therapy (a treatment that lowers testosterone).

Do not take Abritiga 250 mg Tablet 30's if you are allergic to any of its components, if you have severe liver damage, or in combination with Ra-233 (used to treat prostate cancer). Inform your doctor if you have liver problems, high blood pressure, low blood potassium, heart failure, heart or blood vessel problems, irregular or rapid heartbeat, heart rhythm problems, shortness of breath, rapid weight gain, swelling in the legs, ankles, or feet, high blood sugar, bone problems, or if you have taken ketoconazole in the past for prostate cancer. Abritiga 250 mg Tablet 30's may cause libido (decreased sex drive), muscle weakness, decreased red blood cells, and/or muscle pain. Abritiga 250 mg Tablet 30's should not be given in combination with Ra-233 due to an increased risk of bone fracture or death.